Vaxart, INC 10-Q quarterly reports

Vaxart, Inc. reported a net loss of $13.5 million for Q2 2026, with a significant reduction in government contract revenue and continued operational expenses, alongside its delisting from Nasdaq.

Vaxart, Inc. reported Q1 2026 results, showing increased revenue driven by government contracts, while continuing development of its oral COVID-19 and norovirus vaccine candidates.

Vaxart reported a significant increase in government contract revenue and a reduced net loss for Q3 2025, bolstered by a new $30 million upfront deal with Dynavax, which alleviates prior going concern doubts, despite its recent Nasdaq delisting and reduced scope of a key BARDA contract.

Vaxart reports increased Q2 2025 revenue and reduced net loss, but faces a stop work order on its pivotal COVID-19 vaccine trial and Nasdaq delisting, raising significant going concern doubts.

Vaxart, Inc. announces its financial results for the first quarter of 2025, highlighting revenue growth driven by government contracts and providing updates on its vaccine development programs.

Vaxart's Q3 2024 report highlights progress in clinical trials and financial activities, including a significant government contract and capital raises.

Vaxart's second quarter 2024 results show increased revenue from government contracts and a net loss, alongside progress in clinical trials and strategic funding agreements.

Vaxart's first quarter 2024 results show increased revenue from government contracts and non-cash royalties, alongside ongoing research and development expenses.